Haemonetics (HAE) Net Income towards Common Stockholders (2016 - 2025)
Haemonetics has reported Net Income towards Common Stockholders over the past 17 years, most recently at $44.8 million for Q4 2025.
- For Q4 2025, Net Income towards Common Stockholders rose 19.35% year-over-year to $44.8 million; the TTM value through Dec 2025 reached $175.5 million, up 34.88%, while the annual FY2025 figure was $167.7 million, 42.63% up from the prior year.
- Net Income towards Common Stockholders for Q4 2025 was $44.8 million at Haemonetics, up from $38.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $58.0 million in Q1 2025 and troughed at -$11.0 million in Q2 2021.
- A 5-year average of $27.5 million and a median of $32.1 million in 2022 define the central range for Net Income towards Common Stockholders.
- Biggest five-year swings in Net Income towards Common Stockholders: tumbled 162.61% in 2021 and later soared 546.65% in 2022.
- Year by year, Net Income towards Common Stockholders stood at $14.9 million in 2021, then surged by 121.76% to $32.9 million in 2022, then fell by 5.17% to $31.2 million in 2023, then rose by 20.09% to $37.5 million in 2024, then rose by 19.35% to $44.8 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for HAE at $44.8 million in Q4 2025, $38.7 million in Q3 2025, and $34.0 million in Q2 2025.